2021
Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States
Neparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.Peer-Reviewed Original ResearchCurrent equity holderWhite patientsBlack patientsInpatient treatmentVisit ratesTelemedicine uptakeTreatment categoriesPerson visitsHematologic malignanciesAdvisory CommitteeTreatment typeSignificant reductionRacial disparitiesLines of therapyDiagnosis of AMLDe-identified databaseEarly pandemic monthsPotential racial disparitiesCurrent employmentElectronic health recordsFlatiron HealthHospital admissionActive treatmentInitial diagnosisCSL Behring
2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020, 136: 1134-1143. PMID: 32688395, PMCID: PMC7472711, DOI: 10.1182/blood.2020006965.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAnti-Inflammatory AgentsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPandemicsPneumonia, ViralProtein Kinase InhibitorsSARS-CoV-2Survival AnalysisTreatment OutcomeConceptsCOVID-19 diagnosisCLL patientsHigh riskCumulative Illness Rating Scale scoreCOVID-19Intensive care unit admissionOverall case fatality rateChronic lymphocytic leukemia patientsBruton tyrosine kinase inhibitorsMulticenter international experienceCare unit admissionSymptomatic COVID-19Severe acute respiratory syndrome coronavirus 2 infection riskCOVID-19 courseCase fatality rateRating Scale scoresFuture epidemiologic studiesLymphocytic leukemia patientsCoronavirus disease 2019Tyrosine kinase inhibitorsUnit admissionBaseline characteristicsMost patientsHospital admissionImmune dysfunction